The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells Corrigendum in /10.3892/ijo.2022.5408

Wang,Yifei; Han,Alex; Chen,Eva; Singh,Rakesh K.; Chichester,Clinton O.; Moore,Richard G.; Singh,Ajay P.; Vorsa,Nicholi

doi:10.3892/ijo.2015.2931

The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells

Corrigendum in: /10.3892/ijo.2022.5408

Authors:
- Yifei Wang
- Alex Han
- Eva Chen
- Rakesh K. Singh
- Clinton O. Chichester
- Richard G. Moore
- Ajay P. Singh
- Nicholi Vorsa
View Affiliations

Affiliations: Department of Plant Biology and Pathology, Rutgers University, New Brunswick, NJ 08901, USA, Molecular Therapeutics Laboratory, Program in Women's Oncology, Women and Infants' Hospital of Rhode Island, Alpert Medical School, Brown University, Providence, RI 02905, USA, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA
Published online on: March 17, 2015 https://doi.org/10.3892/ijo.2015.2931
Pages: 1924-1934
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cranberry flavonoids (flavonols and flavan-3-ols), in addition to their antioxidant properties, have been shown to possess potential in vitro activity against several cancers. However, the difficulty of isolating cranberry compounds has largely limited anticancer research to crude fractions without well-defined compound composition. In this study, individual cranberry flavonoids were isolated to the highest purity achieved so far using gravity and high performance column chromatography and LC-MS characterization. MTS assay indicated differential cell viability reduction of SKOV-3 and OVCAR-8 ovarian cancer cells treated with individual cranberry flavonoids. Treatment with quercetin aglycone and PAC DP-9, which exhibited the strongest activity, induced apoptosis, led to caspase-3 activation and PARP deactivation, and increased sensitivity to cisplatin. Furthermore, immunofluorescence microscopy and western blot study revealed reduced expression and activation of epidermal growth factor receptor (EGFR) in PAC DP-9 treated SKOV-3 cells. In addition, quercetin aglycone and PAC DP-9 deactivated MAPK-ERK pathway, induced downregulation of cyclin D1, DNA-PK, phospho-histone H3 and upregulation of p21, and arrested cell cycle progression. Overall, this study demonstrates promising in vitro cytotoxic and anti-proliferative properties of two newly characterized cranberry flavonoids, quercetin aglycone and PAC DP-9, against ovarian cancer cells.

View Figures

View References

1	Jacobs IJ and Menon U: Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 3:355–366. 2004. View Article : Google Scholar : PubMed/NCBI
2	Agarwal R and Kaye SB: Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 3:502–516. 2003. View Article : Google Scholar : PubMed/NCBI
3	American Cancer Society. Ovarian Cancer Key Statistics. http://www.cancer.org/cancer/ovariancancer/index. 2014
4	Foo LY, Lu Y, Howell AB and Vorsa N: A-Type proanthocyanidin trimers from cranberry that inhibit adherence of uropathogenic P-fimbriated Escherichia coli. J Nat Prod. 63:1225–1228. 2000. View Article : Google Scholar : PubMed/NCBI
5	Seeram NP, Adams LS, Hardy ML and Heber D: Total cranberry extract versus its phytochemical constituents: Antiproliferative and synergistic effects against human tumor cell lines. J Agric Food Chem. 52:2512–2517. 2004. View Article : Google Scholar : PubMed/NCBI
6	Neto CC: Cranberry and its phytochemicals: A review of in vitro anticancer studies. J Nutr. 137(Suppl): S186–S193. 2007.
7	Neto CC, Krueger CG, Lamoureaux TL, et al: MALDI-TOFMS characterization of proanthocyanidins from cranberry fruit (Vaccinium macrocarpon) that inhibit tumor cell growth and matrix metalloproteinase expression in vitro. J Sci Food Agric. 86:18–25. 2006. View Article : Google Scholar
8	Ferguson PJ, Kurowska E, Freeman DJ, Chambers AF and Koropatnick DJ: A flavonoid fraction from cranberry extract inhibits proliferation of human tumor cell lines. J Nutr. 134:1529–1535. 2004.PubMed/NCBI
9	Singh AP, Singh RK, Kim KK, Satyan KS, Nussbaum R, Torres M, Brard L and Vorsa N: Cranberry proanthocyanidins are cytotoxic to human cancer cells and sensitize platinum-resistant ovarian cancer cells to paraplatin. Phytother Res. 23:1066–1074. 2009. View Article : Google Scholar : PubMed/NCBI
10	Kim KK, Singh AP, Singh RK, Demartino A, Brard L, Vorsa N, Lange TS and Moore RG: Anti-angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells. Int J Oncol. 40:227–235. 2012.
11	Singh AP, Lange TS, Kim KK, Brard L, Horan T, Moore RG, Vorsa N and Singh RK: Purified cranberry proanthocyanidines (PAC-1A) cause pro-apoptotic signaling, ROS generation, cyclophosphamide retention and cytotoxicity in high-risk neuroblastoma cells. Int J Oncol. 40:99–108. 2012.
12	Vvedenskaya IO, Rosen RT, Guido JE, Russell DJ, Mills KA and Vorsa N: Characterization of flavonols in cranberry (Vaccinium macrocarpon) powder. J Agric Food Chem. 52:188–195. 2004. View Article : Google Scholar : PubMed/NCBI
13	Wilson T, Singh AP, Vorsa N, Goettl CD, Kittleson KM, Roe CM, Kastello GM and Ragsdale FR: Human glycemic response and phenolic content of unsweetened cranberry juice. J Med Food. 11:46–54. 2008. View Article : Google Scholar : PubMed/NCBI
14	Singh AP, Wilson T, Kalk AJ, Cheong J and Vorsa N: Isolation of specific cranberry flavonoids for biological activity assessment. Food Chem. 116:963–968. 2009. View Article : Google Scholar :
15	Nicholson RI, Gee JMW and Harper ME: EGFR and cancer prognosis. Eur J Cancer. 37(Suppl 4): S9–S15. 2001. View Article : Google Scholar : PubMed/NCBI
16	Schilder RJ, Hall L, Monks A, Handel LM, Fornace AJ Jr, Ozols RF, Fojo AT and Hamilton TC: Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer. 45:416–422. 1990. View Article : Google Scholar : PubMed/NCBI
17	Bacchetti S and Graham F: Inhibition of cell-proliferation by an adenovirus vector expressing the human wild type-p53 protein. Int J Oncol. 3:781–788. 1993.PubMed/NCBI
18	Anderson NG, Ahmad T, Chan K, Dobson R and Bundred NJ: ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer. 94:774–782. 2001. View Article : Google Scholar : PubMed/NCBI
19	Shen SC, Chen YC, Hsu FL and Lee WR: Differential apoptosis-inducing effect of quercetin and its glycosides in human promyeloleukemic HL-60 cells by alternative activation of the caspase 3 cascade. J Cell Biochem. 89:1044–1055. 2003. View Article : Google Scholar : PubMed/NCBI
20	Murota K, Shimizu S, Chujo H, Moon JH and Terao J: Efficiency of absorption and metabolic conversion of quercetin and its glucosides in human intestinal cell line Caco-2. Arch Biochem Biophys. 384:391–397. 2000. View Article : Google Scholar
21	Yarden Y: The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer. 37(Suppl 4): S3–S8. 2001. View Article : Google Scholar : PubMed/NCBI
22	Sun Q, Prasad R, Rosenthal E and Katiyar SK: Grape seed proanthocyanidins inhibit the invasiveness of human HNSCC cells by targeting EGFR and reversing the epithelial-to-mesenchymal transition. PLoS One. 7:e31093. 2012. View Article : Google Scholar : PubMed/NCBI
23	Rodemann HP, Dittmann K and Toulany M: Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol. 83:781–791. 2007. View Article : Google Scholar : PubMed/NCBI
24	Wang SC and Hung MC: Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res. 15:6484–6489. 2009. View Article : Google Scholar : PubMed/NCBI
25	Liccardi G, Hartley JA and Hochhauser D: EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res. 71:1103–1114. 2011. View Article : Google Scholar : PubMed/NCBI
26	Jamieson ER and Lippard SJ: Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev. 99:2467–2498. 1999. View Article : Google Scholar
27	Jung Y and Lippard SJ: Direct cellular responses to platinum-induced DNA damage. Chem Rev. 107:1387–1407. 2007. View Article : Google Scholar : PubMed/NCBI
28	Stokoe D, Macdonald SG, Cadwallader K, Symons M and Hancock JF: Activation of Raf as a result of recruitment to the plasma membrane. Science. 264:1463–1467. 1994. View Article : Google Scholar : PubMed/NCBI
29	Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
30	Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R and McCubrey JA: Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int J Oncol. 22:469–480. 2003.PubMed/NCBI
31	Hans F and Dimitrov S: Histone H3 phosphorylation and cell division. Oncogene. 20:3021–3027. 2001. View Article : Google Scholar : PubMed/NCBI
32	Chadee DN, Hendzel MJ, Tylipski CP, Allis CD, Bazett-Jones DP, Wright JA and Davie JR: Increased Ser-10 phosphorylation of histone H3 in mitogen-stimulated and oncogene-transformed mouse fibroblasts. J Biol Chem. 274:24914–24920. 1999. View Article : Google Scholar : PubMed/NCBI
33	Agarwal ML, Agarwal A, Taylor WR and Stark GR: p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA. 92:8493–8497. 1995. View Article : Google Scholar : PubMed/NCBI
34	Ciccarelli C, Marampon F, Scoglio A, Mauro A, Giacinti C, De Cesaris P and Zani BM: p21^WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells. Mol Cancer. 4:41. 2005. View Article : Google Scholar
35	Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:805–816. 1993. View Article : Google Scholar : PubMed/NCBI
36	Vermeulen K, Van Bockstaele DR and Berneman ZN: The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003. View Article : Google Scholar : PubMed/NCBI